Physician profile
David A Glusko
NPI 1295737518
$6,656.32
in general payments reported to CMS, 2019-2025
42 companies · $756 in 2025
The $756 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $379 · 2021: $364 · 2022: $1,085 · 2023: $1,529 · 2024: $1,458 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,579 · Education: $113 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,579.20 |
| Education | $113.35 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $893.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $805.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $491.54 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $473.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $436.82 | 2020-2024 | Veozah |
| Lilly USA, LLC | $424.38 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $414.39 | 2019-2025 | |
| Abbott Laboratories | $366.23 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx, Eterna |
| Amgen INC. | $362.21 | 2019-2025 | Evenity, Prolia, Otezla |
| E.R. Squibb & Sons, L.L.C. | $274.37 | 2022-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.32 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $183.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $167.84 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.39 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $93.86 | 2019-2023 | Xarelto |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Glusko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.